Sonali Jindal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sonali Jindal has a total of 454 co-authors. Here are the top co-authors by number of shared publications:
- Padmanee Sharma
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
123 shared publications - Sreyashi Basu
James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, USA
76 shared publications - Rebecca Slack Tidwell
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, USA
69 shared publications - Shalini S. Yadav
Immunotherapy Platform, University of MD Anderson Cancer Center, Houston, Texas. 7
68 shared publications - Marc Macaluso
Immunotherapy Platform, James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
66 shared publications - James Patrick Allison
Department of Immunology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
49 shared publications
Latest Publications
- Open Access
- 8 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial
We report on the randomized portion of the phase 2, open-label CheckMate 650 trial (NCT02985957), in which docetaxel-experienced, biologically male patients with chemotherapy-refractory metastatic castration-resistant prostate cancer were randomized 2:2:1:2 to nivolumab 3 mg /kg plus ipilimumab 1 mg /kg (n = 73), nivolumab 1 mg /kg plus ipilimumab 3 mg /kg (n = 74), ipilimumab 3 mg /kg (n = 38), or cabazitaxel (n = 74). Primary endpoints were objective response rate and radiographic progression-free survival; key secondary endpoints included overall survival, prostate-specific antigen response rate, and safety. This portion of CheckMate 650 was not designed to statistically compare between cohorts. Respectively, objective response rates (95% CI) were 9.3% (2.6-22.1), 19.5% (8.8-34.9), 4.5% (0.1-22.8), and 12.2% (4.1-26.2), and median radiographic progression-free survival (95% CI) was 3.9 (2.2-7.6), 4.2 (3.3-5.6), 3.5 (2.1-5.8), and 7.9 (5.6-9.3) months. Respective incidence of grade ≥3 treatment-related adverse events was 28.8%, 30.1%, 18.4%, and 34.7%. Preliminary post hoc biomarker analyses in patients who received treatment with any immunotherapy regimen (i.e., treated with either of the nivolumab plus ipilimumab regimens or with ipilimumab alone, n = 12) identified a transcriptional signature, derived from the most highly expressed genes across cell types within select perivascular immune niches (comprising CD31+ endothelial, CD14+HLA-DR+ myeloid, and CD4+ and CD8+ T cells), which was associated with prolonged overall survival. These results provide further evidence of antitumor activity with nivolumab plus ipilimumab in select patients with metastatic castration-resistant prostate cancer and nominate a candidate prognostic biomarker that warrants confirmation in future prospective clinical trials.
- 8 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessNivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial
We report on the randomized portion of the phase 2, open-label CheckMate 650 trial (NCT02985957), in which docetaxel-experienced, biologically male patients with chemotherapy-refractory metastatic castration-resistant prostate cancer were randomized 2:2:1:2 to nivolumab 3 mg /kg plus ipilimumab 1 mg /kg (n = 73), nivolumab 1 mg /kg plus ipilimumab 3 mg /kg (n = 74), ipilimumab 3 mg /kg (n = 38), or cabazitaxel (n = 74). Primary endpoints were objective response rate and radiographic progression-free survival; key secondary endpoints included overall survival, prostate-specific antigen response rate, and safety. This portion of CheckMate 650 was not designed to statistically compare between cohorts. Respectively, objective response rates (95% CI) were 9.3% (2.6-22.1), 19.5% (8.8-34.9), 4.5% (0.1-22.8), and 12.2% (4.1-26.2), and median radiographic progression-free survival (95% CI) was 3.9 (2.2-7.6), 4.2 (3.3-5.6), 3.5 (2.1-5.8), and 7.9 (5.6-9.3) months. Respective incidence of grade ≥3 treatment-related adverse events was 28.8%, 30.1%, 18.4%, and 34.7%. Preliminary post hoc biomarker analyses in patients who received treatment with any immunotherapy regimen (i.e., treated with either of the nivolumab plus ipilimumab regimens or with ipilimumab alone, n = 12) identified a transcriptional signature, derived from the most highly expressed genes across cell types within select perivascular immune niches (comprising CD31+ endothelial, CD14+HLA-DR+ myeloid, and CD4+ and CD8+ T cells), which was associated with prolonged overall survival. These results provide further evidence of antitumor activity with nivolumab plus ipilimumab in select patients with metastatic castration-resistant prostate cancer and nominate a candidate prognostic biomarker that warrants confirmation in future prospective clinical trials.
- Open Access
- 9 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Dual phagocytosis-checkpoint blockade revitalizes immune surveillance in mouse models of glioblastoma
Macrophage-mediated phagocytosis of tumor cells elicits potent antitumor immunity. Nonetheless, sole-blockade of the anti-phagocytosis molecule CD47 has yielded insufficient therapeutic outcomes. Here, we report that glioblastoma (GBM) cells expressed abundant levels of phagocytosis checkpoint CD24. We further show that dual blockade of CD24 and CD47 synergistically enhances the pro-phagocytic activity of macrophages, thereby improving tumor antigen cross-presentation and activating the cyclic GMP-AMP synthase–stimulator of interferon genes (cGAS-STING) pathway. This innate immune activation facilitates T cell infiltration into tumors and sensitizes tumors to anti-PD1 therapy, improving survival outcomes in murine GBM models, including immunosuppressive tumors reflecting human GBM-like features. Thus, our results indicate that dual-phagocytosis checkpoint blockade offers a promising therapeutic avenue to potentiate cancer immunotherapy.
- 9 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessDual phagocytosis-checkpoint blockade revitalizes immune surveillance in mouse models of glioblastoma
Macrophage-mediated phagocytosis of tumor cells elicits potent antitumor immunity. Nonetheless, sole-blockade of the anti-phagocytosis molecule CD47 has yielded insufficient therapeutic outcomes. Here, we report that glioblastoma (GBM) cells expressed abundant levels of phagocytosis checkpoint CD24. We further show that dual blockade of CD24 and CD47 synergistically enhances the pro-phagocytic activity of macrophages, thereby improving tumor antigen cross-presentation and activating the cyclic GMP-AMP synthase–stimulator of interferon genes (cGAS-STING) pathway. This innate immune activation facilitates T cell infiltration into tumors and sensitizes tumors to anti-PD1 therapy, improving survival outcomes in murine GBM models, including immunosuppressive tumors reflecting human GBM-like features. Thus, our results indicate that dual-phagocytosis checkpoint blockade offers a promising therapeutic avenue to potentiate cancer immunotherapy.
- Open Access
Spatial immune hubs defined by conserved activated dendritic cells are remodeled by immunotherapy
Dendritic cells (DCs) orchestrate anti-tumor immune responses, yet the full extent of their phenotypic diversity, and spatial dynamics within the tumor microenvironment (TME) remains incompletely understood. Here, we constructed an integrated atlas of tumor-infiltrating DCs by harmonizing single-cell transcriptomic data from 12 murine tumor studies and 28 published human cancer datasets, together with newly generated single-cell-resolved multiplexed tissue imaging across immunotherapy conditions in a murine model. We noted conserved transcriptional states across species, including canonical conventional type 1 DCs (cDC1s), diverse type 2 DC (cDC2) subpopulations, and two activation states characterized by CCR7 expression (CCR7 + DCs) or interferon-stimulated gene expression (ISG⁺ DCs). Spatial transcriptomics analyses from human TMEs revealed that CCR7 + DCs and ISG⁺ DCs reside in distinct T cell-enriched regions that are embedded within distinct signaling environments. High-dimensional multiplexed proteomic imaging demonstrated that these DC-T cell niches undergo divergent remodeling across multiple immunotherapy conditions. Notably, this spatial reorganization occurred despite minimal detectable changes in DC transcriptional states. This study delineates conserved DC activation states and their spatial organization within tumors and captures the therapy-dependent remodeling, providing a framework for studying therapy-associated remodeling of DC immune programs in cancer.
Open AccessSpatial immune hubs defined by conserved activated dendritic cells are remodeled by immunotherapy
Dendritic cells (DCs) orchestrate anti-tumor immune responses, yet the full extent of their phenotypic diversity, and spatial dynamics within the tumor microenvironment (TME) remains incompletely understood. Here, we constructed an integrated atlas of tumor-infiltrating DCs by harmonizing single-cell transcriptomic data from 12 murine tumor studies and 28 published human cancer datasets, together with newly generated single-cell-resolved multiplexed tissue imaging across immunotherapy conditions in a murine model. We noted conserved transcriptional states across species, including canonical conventional type 1 DCs (cDC1s), diverse type 2 DC (cDC2) subpopulations, and two activation states characterized by CCR7 expression (CCR7 + DCs) or interferon-stimulated gene expression (ISG⁺ DCs). Spatial transcriptomics analyses from human TMEs revealed that CCR7 + DCs and ISG⁺ DCs reside in distinct T cell-enriched regions that are embedded within distinct signaling environments. High-dimensional multiplexed proteomic imaging demonstrated that these DC-T cell niches undergo divergent remodeling across multiple immunotherapy conditions. Notably, this spatial reorganization occurred despite minimal detectable changes in DC transcriptional states. This study delineates conserved DC activation states and their spatial organization within tumors and captures the therapy-dependent remodeling, providing a framework for studying therapy-associated remodeling of DC immune programs in cancer.
- Open Access
Macrophage-Dendritic Cell-T-Cell Tetrads Orchestrate Antitumor Immunity and Response to Checkpoint Blockade
Immune checkpoint inhibitors (ICIs) elicit durable responses in only a subset of patients with solid tumors, underscoring the need to define the cellular architectures that govern effective antitumor immunity. Here we identify a spatially organized multicellular immune unit comprising macrophages, cDC1s, CD4+ T-cells, and CD8+ T-cells that emerges in response to anti-CTLA-4 or dual checkpoint blockade. We term these structures tetrads. Using multiplexed imaging and spatial transcriptomics in mouse and human tumors, we show that tetrads assemble early during immune priming, depend on the ICOS-ICOSL pathway, and are enriched for ICOS+ Th1-like CD4+ T cells and ICOSL-high cDC1s. CD8+ T-cells within tetrads exhibit an activated, non-terminally differentiated state, while tetrad-associated macrophages display an interferon gamma-responsive program that sustains CD8+ T-cell function and prevents dysfunction. Functionally, ICOSL+ cDC1s are required for tumor eradication in vivo. In patients with bladder cancer treated with neoadjuvant dual checkpoint blockade, tetrad, but not triad or dyad formation correlates with clinical response. These findings establish tetrads as a fundamental cellular unit coordinating antitumor immunity and responsiveness to ICIs.
Open AccessMacrophage-Dendritic Cell-T-Cell Tetrads Orchestrate Antitumor Immunity and Response to Checkpoint Blockade
Immune checkpoint inhibitors (ICIs) elicit durable responses in only a subset of patients with solid tumors, underscoring the need to define the cellular architectures that govern effective antitumor immunity. Here we identify a spatially organized multicellular immune unit comprising macrophages, cDC1s, CD4+ T-cells, and CD8+ T-cells that emerges in response to anti-CTLA-4 or dual checkpoint blockade. We term these structures tetrads. Using multiplexed imaging and spatial transcriptomics in mouse and human tumors, we show that tetrads assemble early during immune priming, depend on the ICOS-ICOSL pathway, and are enriched for ICOS+ Th1-like CD4+ T cells and ICOSL-high cDC1s. CD8+ T-cells within tetrads exhibit an activated, non-terminally differentiated state, while tetrad-associated macrophages display an interferon gamma-responsive program that sustains CD8+ T-cell function and prevents dysfunction. Functionally, ICOSL+ cDC1s are required for tumor eradication in vivo. In patients with bladder cancer treated with neoadjuvant dual checkpoint blockade, tetrad, but not triad or dyad formation correlates with clinical response. These findings establish tetrads as a fundamental cellular unit coordinating antitumor immunity and responsiveness to ICIs.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
Figure S3. (A) Average time that study participants wore the Fitbit throughout the study; (B) Resting heart rate in study participants at baseline; (C) Average total minutes of exercise at heart rate 70-85% of PHR; (D) Average total minutes of exercise at heart rate >85% of PHR. (***, P ≤0.001; ****, P≤0.0001).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
Figure S3. (A) Average time that study participants wore the Fitbit throughout the study; (B) Resting heart rate in study participants at baseline; (C) Average total minutes of exercise at heart rate 70-85% of PHR; (D) Average total minutes of exercise at heart rate >85% of PHR. (***, P ≤0.001; ****, P≤0.0001).
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
Table S3. Number of patients experiencing adverse events. Only those toxicities experienced while on the trial are presented in the table. Toxicities during the pre-study stage of the trial, for example, that were present before participants begin intervention were not included. Should a patient experience an adverse event more than once, the patient is only counted once at the highest grade for that adverse event.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
Table S3. Number of patients experiencing adverse events. Only those toxicities experienced while on the trial are presented in the table. Toxicities during the pre-study stage of the trial, for example, that were present before participants begin intervention were not included. Should a patient experience an adverse event more than once, the patient is only counted once at the highest grade for that adverse event.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
Figure S2. CYCLE-P trial study visits and follow-up.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
Figure S2. CYCLE-P trial study visits and follow-up.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
Figure S8. (A) Volcano plot of statistically significant genes and fold-changes between the usual care and exercise groups in DSP assay. Top significantly differentially expressed genes are labeled; (B) The dot plot presents enriched GSEA HALLMARK pathways. The sizes of the dots represent the count of core enrichment (leading-edge) genes. The colors of the dots represent the BH-adjusted P-values. The order of HALLMARK gene sets is based on the gene ratio (number of significant genes associated with the HALLMARK gene sets / total number of significant genes; (C) Total CD8+ T cell density per mm2 (left) and epithelial (right) in colonic mucosa preand post- intervention from usual care (n=4) and exercise (n=4) participants; (D) Total CD57+ NK cell density per mm2 (left) and epithelial (right) in colonic mucosa pre- and post- intervention from usual care (n=4) and exercise (n=4) participants.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
Figure S8. (A) Volcano plot of statistically significant genes and fold-changes between the usual care and exercise groups in DSP assay. Top significantly differentially expressed genes are labeled; (B) The dot plot presents enriched GSEA HALLMARK pathways. The sizes of the dots represent the count of core enrichment (leading-edge) genes. The colors of the dots represent the BH-adjusted P-values. The order of HALLMARK gene sets is based on the gene ratio (number of significant genes associated with the HALLMARK gene sets / total number of significant genes; (C) Total CD8+ T cell density per mm2 (left) and epithelial (right) in colonic mucosa preand post- intervention from usual care (n=4) and exercise (n=4) participants; (D) Total CD57+ NK cell density per mm2 (left) and epithelial (right) in colonic mucosa pre- and post- intervention from usual care (n=4) and exercise (n=4) participants.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
Table S6. Gene set enrichment analysis using the KEGG pathways and Gene Ontology Biological Processes databases. Pathways statistically significant activated or suppressed after twelve months exercise are displayed (BH-adjusted P-value<0.05).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
Table S6. Gene set enrichment analysis using the KEGG pathways and Gene Ontology Biological Processes databases. Pathways statistically significant activated or suppressed after twelve months exercise are displayed (BH-adjusted P-value<0.05).
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
Figure S4. Relative change in prostaglandin metabolite levels after twelve months follow-up in usual care and exercise groups (A-C, Wilcoxon signed-rank test; ns, P>0.05; *, P ≤0.05; **, P≤0.01).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
Figure S4. Relative change in prostaglandin metabolite levels after twelve months follow-up in usual care and exercise groups (A-C, Wilcoxon signed-rank test; ns, P>0.05; *, P ≤0.05; **, P≤0.01).